Analysis of Newly Expanded Cumulative Cohort Demonstrates that DecisionDx-Melanoma Improves Risk Prediction for Patients with Cutaneous Melanoma


FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of newly expanded performance results for DecisionDx®-Melanoma at the 2019 Fall Clinical Dermatology Conference for PAs & NPs held in Scottsdale, Arizona. The poster, titled “The prognostic 31-gene expression profile (31-GEP) test improves risk prediction in cutaneous melanoma (CM)….